Founded in 1451, the University of Glasgow (UGLA) has a tradition of excellence as the fourth oldest university in the UK. It is a member of the elite Russell Group of leading UK research universities, is ranked in the world’s top 100 universities and was the Scottish University of the year 2018 (The Times and The Sunday Times Good University Guide). It is also the first university in the UK to be rated as five Stars Plus overall in QS World University Rankings 2019.
The HEALIKICK team at University of Glasgow brings together biomedical research themes in the areas
of Biomaterials and Cell and Systems Biology. The team is part of the Centre for the for the Cellular Microenvironment (https://glasgow.thecemi.org) and benefits from strong links to the UK Regenerative Medicine Platform, the UK Cell & Gene Therapy Catapult, to the biomedical sciences and clinical medicine community, and to local and international industry.
We are currently home to 30+ PhD students and post-doctoral level researchers in our labs with projects ranging from basic material and biological science up to projects containing translational clinical components. We bring to HEALIKICK extensive expertise in biomaterial engineering, manufacturing of advanced coatings, plasma polymerization, stem cell biology and engineering, molecular biology and in vivo models of bone regeneration. ULGA will contribute expertise of in vitro stem cell biology to characterize the therapeutic technologies being developed and also background processes relating to the manufacture of the medical device and ATMP.
The University of Strathclyde is a leading international technological university, established in 1796 as a place of ‘useful learning.’ The University is committed to research, teaching, useful learning and employability, with strong links to industry and support for innovation and commercialisation. The University was ranked in the UK’s top 20 universities for research intensity according to the Times Higher Education’s analysis of REF2014, and has one of the largest and best equipped Engineering faculties. The Department of Biomedical Engineering is one of the oldest homes of biomedical teaching and research in the world, and is located within the dedicated, newly refurbished Wolfson Building, with recent investment of £16M. Biomedical research is split across 3 themes – cell and tissue engineering, medical devices, and rehabilitation technologies.
Histocell is a private biopharmaceutical company focused on the development, manufacturing and commercialization of novel medical devices, active ingredients and cell therapy drugs for regenerative medicine.
Our products have a common therapeutic approach focused in the protection and regeneration of tissues damaged by inflammatory and oxidative environments and are backed up by a strong intellectual protection with 53 patents till date.
Histocell counts on a highly qualified multidisciplinary team, made of professionals from both academic and industry fields, including 9 PhDs.
The company counts with a fully equipped production unit for advanced therapy medicinal products, certified by the Spanish Drug Agency (AEMPS) form 2011 for pan-European use. From September 2018, we’ve got our own medical device manufacturing facility of 2000 m2, fully equipped, near the city of Bilbao.
The overarching research area of the Department is biological materials science, which connects materials science and biology in a reciprocal way: First, biomedical questions are addressed by methods and approaches borrowed from physics, chemistry or materials science. One such example is the extracellular tissue in the case of skeletal diseases and during regeneration. Second, we tap into the diversity of natural organisms to study naturally evolved solutions of engineering problems encountered by these organisms. Examples are materials combining stiffness and fracture resistance or providing capabilities for sensing, self-healing or shape-change. Many types of natural materials, often based on common classes of natural polymers, such as cellulose, chitin or protein are addressed in these ways.
Biodonostia Health Research Institute is one of the main health research centres of Osakidetza SVS (the Basque Health Service). It was founded in San Sebastian in 2010 and the prestigious Carlos III Institute of Health (ISCIII) has accredited it as one of the reference Health Research Institutes in Spain since 2011. Biodonostia HRI preferentially boosts translational research focusing on the patient. It covers all research carried out in Gipuzkoa within the framework of the Basque Health Service (Osakidetza – SVS) and aims to improve people’s health through its multi-institutional and inter-disciplinary collaborative structure. The research is arranged in 7 subject areas that bring together around 350 researchers in 29 groups in the following areas: neurosciences, gastrointestinal and liver disorders, infectious diseases, oncology, systemic diseases, epidemiology and bioengineering. Other cross-cutting research areas include ageing and personalised medicine. It also has access to key research platforms.
The University of Navarra (UNAV) is a non-profit private university based at the southeast border of Pamplona, Spain. The Biomedicine campus comprises the School of Medicine, the Faculty of Sciences, the School of Pharmacy, the University Clinic of Navarra (CUN) and two research centres. CUN is a reference centre in Spain for several procedures, including Regenerative Medicine strategies. The Cellular Therapy Area (CTA) co-ordinates a multidisciplinary team of basic and clinical research in UNAV-CUN. CTA vision is to deliver new frontline treatments through interdisciplinary research into basic disease mechanisms and the application of novel therapeutic approaches and technology. The expertise of CTA includes state-of-the-art stem cell know-how (hiPSC derivation, growth, gene editing and differentiation), NGS (single cell and bulk RNAseq, ATACseq, ChiPseq, etc.) as well as small and large animal models of disease amongst others.